Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial
Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon… - …, 2016 - ingentaconnect.com
Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
[PDF][PDF] Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon… - Circulation, 2016 - academia.edu
Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon… - Circulation, 2016 - europepmc.org
Background This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon… - Circulation, 2016 - cir.nii.ac.jp
< jats: sec>< jats: title> Background—</jats: title>< jats: p> This randomized controlled trial
evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for …
evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for …
[HTML][HTML] Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon… - Circulation, 2016 - ncbi.nlm.nih.gov
Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon… - 2016 - pubmed.ncbi.nlm.nih.gov
Background This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …